Recurrent or Refractory Glypican 3 (GPC3)
1 clinical trials · Condition
◉ Watch Recurrent or Refractory Glypican 3 (GPC3)
| Record | Firm | Date |
|---|---|---|
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (NCT04928677) | Memorial Sloan Kettering Cancer Center | 2021-06-09 |
Track Recurrent or Refractory Glypican 3 (GPC3) automatically
Every clearance here is in the API, with alerts when new ones post.